View Future GrowthADC Therapeutics 과거 순이익 실적과거 기준 점검 0/6ADC Therapeutics은 연평균 7.4%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 36.2%의 비율로 증가했습니다. 매출은 연평균 6%의 비율로 증가했습니다.핵심 정보7.42%순이익 성장률16.18%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률5.98%자기자본이익률n/a순이익률-173.02%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 05First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$0.21 loss per share (improved from US$0.36 loss in 1Q 2025). Revenue: US$20.9m (down 9.5% from 1Q 2025). Net loss: US$33.0m (loss narrowed 15% from 1Q 2025). Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) missed analyst estimates by 4.1%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 10Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: US$1.12 loss per share (improved from US$1.63 loss in FY 2024). Revenue: US$81.4m (up 15% from FY 2024). Net loss: US$142.6m (loss narrowed 9.6% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 20%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 25% per year.Reported Earnings • Nov 11Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: US$0.30 loss per share (improved from US$0.42 loss in 3Q 2024). Revenue: US$16.4m (down 11% from 3Q 2024). Net loss: US$41.0m (loss narrowed 6.8% from 3Q 2024). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) exceeded analyst estimates by 17%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 13Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2025 results: US$0.50 loss per share (further deteriorated from US$0.38 loss in 2Q 2024). Revenue: US$18.8m (up 8.2% from 2Q 2024). Net loss: US$56.6m (loss widened 55% from 2Q 2024). Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) missed analyst estimates by 4.5%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.Reported Earnings • May 15First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: US$0.36 loss per share (improved from US$0.56 loss in 1Q 2024). Revenue: US$23.0m (up 28% from 1Q 2024). Net loss: US$38.6m (loss narrowed 17% from 1Q 2024). Revenue exceeded analyst estimates by 30%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 27Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: US$1.63 loss per share (improved from US$2.94 loss in FY 2023). Revenue: US$70.8m (up 1.8% from FY 2023). Net loss: US$157.8m (loss narrowed 34% from FY 2023). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) exceeded analyst estimates by 4.1%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates내러티브 업데이트 • Jun 11ADCT: Future Earnings Potential Will Rely On Managing LOTIS-5 Safety RisksNarrative Update: ADC Therapeutics Analyst Price Target Reset Analysts have cut their average price target for ADC Therapeutics to $2, from prior estimates closer to $6. This reflects concerns about Zynlonta's risk benefit profile and added regulatory risk following the LOTIS-5 trial results.속보 • Jun 07ZYNLONTA Study Meets Main Goal as Safety and Regulatory Questions Weigh on ADC TherapeuticsADC Therapeutics reported that its Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in relapsed or refractory DLBCL met the primary endpoint with a statistically significant improvement in progression-free survival versus the control regimen. The trial also showed higher complete response rates and longer durations of response for the ZYNLONTA arm, while overall survival was not negatively affected compared with the control group. Regulators and investors are watching safety closely after the study revealed a higher incidence of serious adverse events, treatment-related deaths and more treatment discontinuations in the ZYNLONTA arm. RBC Capital downgraded the stock to Sector Perform following these findings. The key question now is how regulators weigh the efficacy outcomes against the reported safety issues, particularly for older patients who appeared more affected in the trial. Until there is clearer feedback from the FDA and more visibility on the timing and content of any filing, this appears to be a stock where regulatory decisions could have a significant impact on sentiment and perceived risk.Seeking Alpha • Jun 06ADC Therapeutics: 'Sell' LOTIS-5 Underwhelms And Possible Change In StrategySummary ADC Therapeutics is downgraded from 'Strong Buy' to 'Sell' due to safety concerns in ZYNLONTA's phase 3 LOTIS-5 trial. While ZYNLONTA + rituximab met the primary PFS endpoint, the regimen showed higher serious adverse events and Grade 5 TEAEs versus the comparator. Lack of overall survival benefit and increased withdrawals further undermine the risk-benefit profile for 2nd-line r/r DLBCL expansion. Strategic alternatives, including cost reductions, are under consideration, as regulatory and commercial prospects for ZYNLONTA become uncertain. Read the full article on Seeking AlphaBreakeven Date Change • Jun 05No longer forecast to breakevenThe 6 analysts covering ADC Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$11.8m in 2028. New consensus forecast suggests the company will make a loss of US$18.4m in 2028.New Risk • Jun 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Negative equity (-US$216m). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding).Price Target Changed • Jun 04Price target decreased by 15% to US$6.80Down from US$8.00, the current price target is an average from 5 analysts. New target price is 415% above last closing price of US$1.32. Stock is down 62% over the past year. The company is forecast to post a net loss per share of US$0.84 next year compared to a net loss per share of US$1.12 last year.공시 • Jun 04ADC Therapeutics Announces Topline Results From LOTIS-5 Phase 3 Confirmatory Trial Of ZYNLONTA In Combination with Rituximab In Relapsed or Refractory Diffuse Large B-Cell LymphomaADC Therapeutics announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA plus rituximab achieved statistical significance on the trial's primary endpoint of progression-free survival (PFS) and demonstrated no detrimental effect on the key secondary efficacy endpoint of overall survival (OS). In addition, a higher complete response (CR) rate and duration of CRs (DoCR) were observed with ZYNLONTA plus rituximab. Overall, treatment emergent adverse event (TEAE) rates were similar between arms. Similar rates of overall Grade =3 TEAEs greater than 5% were observed across both arms, with hematologic TEAEs higher in the control arm and infection, hepatotoxicity, and edema/effusion higher in the test arm. Serious adverse events (SAEs), TEAEs leading to study drug withdrawal, and Grade 5 events were higher in the test arm, with the majority of Grade 5 TEAEs in the test arm occurring in patients aged 75 years or older. The LOTIS-5 trial is a randomized, open-label, two-arm, multicenter study evaluating ZYNLONTA plus rituximab versus the standard immunochemotherapy rituximab gemcitabine-oxaliplatin (R-GemOx), for the treatment of r/r DLBCL after one or more lines of systemic therapy. The study met the primary endpoint of PFS (per independent review committee) with statistical significance (HR = 0.73; p-value = 0.008 two sided), with a median PFS of 6.1 months for ZYNLONTA plus rituximab vs 4.7 months for R-GemOx. Overall survival showed no detrimental effect with ZYNLONTA plus rituximab compared to the control arm (HR = 0.96, impacted by the earlier use and a higher rate of new anti-lymphoma treatment switching in the control arm). Overall response rate (ORR) was 58.1% vs. 45.2%, CR rate was 39.5% vs. 26.7%, median duration of response (DOR) was 9.2 months vs. 7.7 months, and median DoCR was 16.8 months vs. 12.3 months for ZYNLONTA plus rituximab compared to R-GemOx, respectively. Of patients achieving CR, 48.5% vs. 16.7% remained in CR at 24 months in favor of ZYNLONTA plus rituximab. Of note, results in North America were consistent with the overall study results. Overall, TEAE rates were similar between arms (98.5% vs. 97.5%). Higher rates of SAEs were seen in the test arm (49.0% vs. 34.5%). Grade =3 TEAEs observed in > 5% of patients were hematologic (40.7% vs. 59.4%), followed by infection/infestations (24.5% vs. 15.7%), then hepatotoxicity (17.2% vs. 8.1%) and oedema/effusion (7.4% vs. 0.5%) when comparing ZYNLONTA plus rituximab to R-GemOx. A higher rate of Grade 5 TEAEs was observed in the ZYNLONTA plus rituximab arm (27 pts/13.2%) vs. R-GemOx (9 pts/4.6%). Of note, the majority of Grade 5 TEAEs in the test arm occurred in patients aged 75 years or older. Higher rates of TEAEs leading to any drug withdrawal occurred in the ZYNLONTA plus rituximab arm (25.5% vs. 9.1%). In this study, the TEAE reporting window was defined as 105 days after the last dose of study treatment or the start of new anticancer therapy, whichever is earlier. The rates of TEAEs in this study were impacted by the longer overall TEAE observation time in the test vs. control arm. This difference is primarily driven by a higher rate of and earlier switching to subsequent therapies in the control arm. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.내러티브 업데이트 • May 28ADCT: Higher Revenue And Margin Assumptions Will Support Future Earnings PotentialAnalysts have raised their price target for ADC Therapeutics by $1, citing updated assumptions around revenue growth, profit margins, and future P/E expectations as key drivers of the revision. Analyst Commentary While the latest price target revision for ADC Therapeutics reflects updated assumptions on revenue, margins, and P/E, bearish analysts continue to flag several risks that could limit upside if execution falls short.분석 기사 • May 07Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter ReportIt's been a good week for ADC Therapeutics SA ( NYSE:ADCT ) shareholders, because the company has just released its...Reported Earnings • May 05First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$0.21 loss per share (improved from US$0.36 loss in 1Q 2025). Revenue: US$20.9m (down 9.5% from 1Q 2025). Net loss: US$33.0m (loss narrowed 15% from 1Q 2025). Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) missed analyst estimates by 4.1%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.내러티브 업데이트 • May 03ADCT: Updated Capital Plans And Refined Assumptions Will Support Future Upside PotentialAnalysts have increased their price target on ADC Therapeutics by $1, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E that they believe better align the valuation with current fundamentals and expectations. Analyst Commentary Despite the modest $1 lift in the price target, recent commentary around ADC Therapeutics still carries a cautious tone.내러티브 업데이트 • Apr 19ADCT: Refined Risk And Earnings Assumptions Will Support Future Upside PotentialAnalysts raised their price target on ADC Therapeutics by $1, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that collectively fine tune their outlook rather than overhaul it. Analyst Commentary Bearish analysts are treating the latest US$1 price target adjustment as a refinement rather than a signal of strong conviction, and their commentary leans cautious around execution, valuation and growth visibility.공시 • Apr 13ADC Therapeutics SA, Annual General Meeting, Jun 01, 2026ADC Therapeutics SA, Annual General Meeting, Jun 01, 2026, at 15:00 W. Europe Standard Time.내러티브 업데이트 • Apr 05ADCT: Refreshed Revenue And Margin Assumptions Will Strengthen Future Earnings PowerAnalysts have lifted their price target on ADC Therapeutics by $1, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the change. Analyst Commentary While the latest price target adjustment reflects refreshed modeling on discount rates, revenue assumptions, margins and future P/E, bearish analysts are still flagging several areas of concern that they see as reasons to stay cautious.내러티브 업데이트 • Mar 21ADCT: Higher Revenue Assumptions Will Support Stronger Future Earnings PowerAnalysts have lifted their price target fair value for ADC Therapeutics from $5.00 to $6.00, citing updated assumptions for revenue growth, profit margins and future P/E that change their overall assessment of risk and return. Valuation Changes Fair Value: raised from $5.00 to $6.00 per share, indicating a higher assessed intrinsic value.Major Estimate Revision • Mar 17Consensus estimates of losses per share improve by 28%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from US$78.5m to US$80.8m. EPS estimate increased from -US$1.11 per share to -US$0.806 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target up from US$7.80 to US$8.00. Share price fell 14% to US$4.11 over the past week.New Risk • Mar 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$186m). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$1.6m net loss in 3 years).Breakeven Date Change • Mar 11No longer forecast to breakevenThe 6 analysts covering ADC Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$13.2m in 2028. New consensus forecast suggests the company will make a loss of US$1.63m in 2028.Reported Earnings • Mar 10Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: US$1.12 loss per share (improved from US$1.63 loss in FY 2024). Revenue: US$81.4m (up 15% from FY 2024). Net loss: US$142.6m (loss narrowed 9.6% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 20%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 25% per year.내러티브 업데이트 • Mar 04ADCT: Higher Revenue Outlook And Richer P/E Multiple Will Support UpsideAnalysts have trimmed their price target on ADC Therapeutics to $7.50 from $8.20, citing updated assumptions that combine higher projected revenue growth with lower expected profit margins and a higher future P/E multiple. Valuation Changes Fair Value: reduced from $8.20 to $7.50, a modest cut to the target level used in the model.Price Target Changed • Mar 03Price target decreased by 8.5% to US$7.50Down from US$8.20, the current price target is an average from 4 analysts. New target price is 85% above last closing price of US$4.05. Stock is up 126% over the past year. The company is forecast to post a net loss per share of US$1.41 next year compared to a net loss per share of US$1.62 last year.분석 기사 • Feb 05ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is LackingADC Therapeutics SA's ( NYSE:ADCT ) price-to-sales (or "P/S") ratio of 6.7x might make it look like a buy right now...Breakeven Date Change • Dec 31Forecast to breakeven in 2028The 6 analysts covering ADC Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.26m in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$238m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding).공시 • Dec 04ADC Therapeutics SA Announces Updated Data from Lotis-7 Phase 1B Clinical Trial of Zynlonta®? in Combination with Bispecific Antibody Supporting Potential Best-In-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaADC Therapeutics SA announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA®? in combination with the bispecific antibody glofitamab (COLUMVI®?) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Enrollment in the LOTIS-7 clinical trial is ongoing, with complete enrollment of approximately 100 patients at the selected 150 ug/kg dose expected during the first half of 2026. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or ref refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphomas (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented, the timing and outcome of the full LOTIS-7 trial, potential best-in-class results, future publication, compendia and regulatory strategy and the commercial opportunity; the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the strengthened balance sheet and expected cash run into at least 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA revenue in the United States and potential peak revenue; the ability of partners to commercialize ZYNLONTA in foreign markets, the timing and amount of future revenue and payments to the company from such partnerships and their ability to obtain regulatory approval for ZYNLONTA™? in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for their excan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for the Company's indebtedness; and the company's indebtedness; and the ability to obtain financial and other assets for the Company's indebtedness.공시 • Dec 03ADC Therapeutics SA to Provide Update on LOTIS-7 Clinical TrialADC Therapeutics SA announced to provide an update on the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker.Reported Earnings • Nov 11Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: US$0.30 loss per share (improved from US$0.42 loss in 3Q 2024). Revenue: US$16.4m (down 11% from 3Q 2024). Net loss: US$41.0m (loss narrowed 6.8% from 3Q 2024). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) exceeded analyst estimates by 17%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.공시 • Oct 14ADC Therapeutics SA announced that it expects to receive $60.02 million in funding from TCG Crossover Management, LLC, Redmile Group, LLCADC Therapeutics SA announced a private placement and entered into a purchase agreement to issue 11,300,000 common shares at a price of $4 per share for aggregate proceeds of $45,200,000 and 3,800,000 Pre-funded warrants at a price of $3.9 per warrant for aggregate proceeds of $14,820,000 and total gross proceeds amounting to $60,020,000. The pre-funded warrants will have an exercise price of $0.099. The transaction is expected to close on October 27, 2025, and will include participation from lead investor TCGX and Redmile Group among other Investors.분석 기사 • Sep 30ADC Therapeutics SA (NYSE:ADCT) Held Back By Insufficient Growth Even After Shares Climb 31%Despite an already strong run, ADC Therapeutics SA ( NYSE:ADCT ) shares have been powering on, with a gain of 31% in...Reported Earnings • Aug 13Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2025 results: US$0.50 loss per share (further deteriorated from US$0.38 loss in 2Q 2024). Revenue: US$18.8m (up 8.2% from 2Q 2024). Net loss: US$56.6m (loss widened 55% from 2Q 2024). Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) missed analyst estimates by 4.5%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.Major Estimate Revision • Aug 12Consensus EPS estimates fall by 14%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$1.52 to -US$1.73 per share. Revenue forecast of US$78.9m unchanged since last update. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$8.20 unchanged from last update. Share price rose 6.5% to US$2.94 over the past week.New Risk • Jul 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$238m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$103m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding).공시 • Jun 30+ 5 more updatesADC Therapeutics SA(NYSE:ADCT) dropped from Russell 3000E Value IndexADC Therapeutics SA(NYSE:ADCT) dropped from Russell 3000E Value Index공시 • Jun 18ADC Therapeutics SA Announces Updated ZYNLONTA®? Investigator-Initiated Trial Data in R/R Marginal Zone LymphomaADC Therapeutics SA announced updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA® to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented during a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on June 20. In addition to the MZL poster presentation at ICML, an oral encore presentation of the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) will also be presented at ICML June 20 at 3:00 p.m. CEST. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed and refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphom (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. Factors that may cause such differences include, but are not limited to: future safety and efficacy results of the Phase 2 IIT in MZL and any regulatory or compendia pathways; the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA revenue in the United States and potential peak revenue; the ability of partners to commercialize ZYNLONTA in foreign markets, the timing and amount of future revenue and payments to the company's such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by the Company's activities by the U.S. and the restrictions imposed on the company's activities by the company's activities by the Company's financial and financial requirements.Price Target Changed • Jun 15Price target increased by 7.3% to US$8.80Up from US$8.20, the current price target is an average from 5 analysts. New target price is 146% above last closing price of US$3.58. Stock is up 8.5% over the past year. The company is forecast to post a net loss per share of US$1.57 next year compared to a net loss per share of US$1.62 last year.공시 • Jun 13ADC Therapeutics SA announced that it expects to receive $100.000002 million in funding from Redmile Group, LLC and other invetsorsADC Therapeutics SA announced that it has entered into a securities purchase agreement to issue 13,031,161 common shares at a price of $3.53 per share for the gross proceeds of $45,999,998.33, 15,734,267 pre-funded warrant at a price of $3.432 per warrant for the gross proceeds of $54,000,004.344 for the total gross proceeds of $100,000,002.674 on June 11, 2025. The warrants will exercisable into 15,734,267 common shares. The pre-funded warrants are exercisable at any time after their original issuance until the tenth anniversary of their original issuance. At any time during the last 90 days of the term, the holder may exchange the pre-funded warrant for, and the Company will issue, a new pre-funded warrant for the number of common shares then remaining under the pre-funded warrant. The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part (but not for less than a common share) by delivering to the Company a duly executed exercise notice and by payment of the aggregate exercise price; provided that any exercise of the pre-funded warrants must be for at least 50,000 common shares (or, if less, the remaining common shares available for purchase under the pre-funded warrants).The transaction will include participation from lead investor, Redmile Group, LLC and includes participation from other institutional investors. The transaction is expected to close on June 16, 2025, subject to customary closing conditions.공시 • Jun 12Adc Therapeutics Announces Updated Data from Lotis-7 Clinical Trial Presented At the European Hematology Association 2025 CongressADC Therapeutics SA announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) to be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The Company will host a conference call and webcast featuring LOTIS-7 trial principal investigator and EHA presenting author, Juan Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine June 12, 2025 at 8:00 a.m. ET to discuss the results. The presentation highlights updated data as of April 14, 2025, in which r/r LBCL patients received dose levels of 120 µg/kg or 150 µg/kg of ZYNLONTA plus the bispecific antibody glofitamab, with 41 patients evaluable for safety and 30 patients evaluable for efficacy. Key highlights of the LOTIS-7 data presentation are as follows: Best overall response data among the 30 efficacy evaluable patients shows overall response rate (ORR) of 93.3% (28/30 pts) as assessed by Lugano Criteria; Complete response (CR) rate of 86.7% (26/30 pts); Of these, 25/26 patients achieving CR remain in CR as of the data cut-off; Median time to CR in 120 µg/kg = 80 days, Median time to CR in 150 µg/kg = 42 days; 12 patients converted from stable disease (SD) or partial response (PR) to CR over time (1 and 11 pts respectively); Of the 6 patients previously treated with CAR-T and undergoing response assessment, 5 achieved a CR; Among the 41 safety evaluable patients, the combination was generally well tolerated with a manageable safety profile and no DLTs across dose levels; Grade 3 or higher treatment emergent adverse events (TEAEs) observed in > 5% of patients included neutropenia (24.4%), anemia (9.8%), AST increased (7.3%), GGT increased (7.3%), and thrombocytopenia (7.3%); In the 150 µg/kg dose, cytokine release syndrome (CRS) (23.8%), all of which were Grade 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) (4.8%), with one case of Grade 2, were observed; In the 120 µg/kg dose, CRS all grades (55%), all of which were Grade 1/2 except one case of Grade 3, and ICANS (10%), with one case of Grade 1 and one case of Grade 2, were observed; TEAEs leading to discontinuation included 3 each for ZYNLONTA and glofitamab; There were no Grade 5 TEAEs observed. This data will be shared at EHA2025 during a poster presentation on June 14 at 6:30 p.m. CEST and also as an oral encore presentation at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20 at 9:00 a.m. ET. The Company plans to share additional data before the end of 2025.공시 • Jun 06ADC Therapeutics SA Elects Timothy Coughlin as DirectorADC Therapeutics SA announced that at its AGM held on June 3, 2025, elected Timothy Coughlin as director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of shareholders. Timothy Coughlin, 58, became a member of board of directors upon election at the Annual Meeting. From 2002 to 2018, Mr. Coughlin was with Neurocrine Biosciences, becoming the Chief Financial Officer of Neurocrine Biosciences in 2006. Prior to joining Neurocrine, he was with Catholic Health Initiatives, where he served as Vice President of Financial Services. He also served on the board of directors of Peloton Therapeutics prior to its sale to Merck & Co in 2019 and Fate Therapeutics from 2013 to 2025. In addition to board of directors, he currently serves on the board of directors of Travere Therapeutics and is chairman of the board at aTyr Pharma. Mr. Coughlin holds a master’s degree in international business from San Diego State University and a bachelor’s degree in accounting from Temple University. Mr. Coughlin is a certified public accountant (CPA) in both California and Pennsylvania.분석 기사 • May 27Shareholders Will Likely Find ADC Therapeutics SA's (NYSE:ADCT) CEO Compensation AcceptableKey Insights ADC Therapeutics to hold its Annual General Meeting on 3rd of June CEO Ameet Mallik's total compensation...분석 기사 • May 17Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest ResultsADC Therapeutics SA ( NYSE:ADCT ) just released its first-quarter report and things are looking bullish. Results...Reported Earnings • May 15First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: US$0.36 loss per share (improved from US$0.56 loss in 1Q 2024). Revenue: US$23.0m (up 28% from 1Q 2024). Net loss: US$38.6m (loss narrowed 17% from 1Q 2024). Revenue exceeded analyst estimates by 30%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.공시 • May 15ADC Therapeutics SA Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)ADC Therapeutics SA announced data presentations from the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with glofitamab in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Updated results will be shared at the European Hematology Association 2025 Congress (EHA2025) taking place in Milan, Italy with an oral core presentation at the 18thInternational Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. Updated LOTIS-5 safety run-in data evaluating the combination of ZYNLONTA plus rituximab (Lonca-R) will also be featured at EHA2025. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (lofitamab tesirine- LPyl) for the treatment of adult patients with relapsed or refractory (r/r") large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphomas (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ADC Therapeutics' CD19-directed ADC ZYNLONTA (lancastuximab tesIRine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymph cancer after two or more lines ofsystem therapy, including diffuse large B -cell lymphoma (DLBC Lonca-R) not otherwise specified (N OS), DLBCL arising from high-grade lymphoma and also low-grade B-cell lymphomas. This indication is approved by The FDA under accelerated approval and in The European Union under conditional approval based On overall response rate and continued approval of this indication may be contingent upon verify and description of clinical benefit in an confirmatory trial. ADC Theraputics' CD19-directed AD19-directed ADC ZY NLONTA (loncastuxIMab tesirine-LPyl) received accelerated approval by The FDA and conditional approval from the Europe Commission for the treatment of rel relapsed or refractory large B-cell lymphoma After two or more lines of systemic treatment. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA revenue in the United States; the ability of partners to commercialize ZYNLONTA in foreign markets, the timing and amount of future revenue and payments to the company from such partnerships and their ability to obtain regulatory approval for ZYNLONTA®? in foreign markets, the timing & amount of future revenue and payments of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, ADCT 602, as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Health Health and Drug Administration (ADCs) and the Company's indebtedness, and the Company's debt and Drug Administration (ADCs).공시 • Apr 22ADC Therapeutics SA, Annual General Meeting, Jun 03, 2025ADC Therapeutics SA, Annual General Meeting, Jun 03, 2025. Location: at the company headquarters, at biopole, route de la corniche 3b, switzerland., epalinges United States분석 기사 • Apr 04ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching RevenuesUnfortunately for some shareholders, the ADC Therapeutics SA ( NYSE:ADCT ) share price has dived 31% in the last thirty...새로운 내러티브 • Apr 03Expanding ZYNLONTA Trials Will Broaden DLBCL Treatment Options Expanding ZYNLONTA into earlier lines of DLBCL through trials could significantly boost revenue by accessing a larger patient population. Reported Earnings • Mar 27Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: US$1.63 loss per share (improved from US$2.94 loss in FY 2023). Revenue: US$70.8m (up 1.8% from FY 2023). Net loss: US$157.8m (loss narrowed 34% from FY 2023). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) exceeded analyst estimates by 4.1%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.Seeking Alpha • Mar 25ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025Summary ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million in cash but faces a net loss, with a cash runway of approximately two years. The company's near-term success hinges on the results of the LOTIS-5 trial, crucial for confirming Zynlonta's efficacy and potential market expansion. Despite a challenging competitive landscape, ADCT's current valuation and cash position make it a high-risk/high-reward investment, meriting a "Buy" sentiment with caution. Read the full article on Seeking Alpha분석 기사 • Mar 10Does This Valuation Of ADC Therapeutics SA (NYSE:ADCT) Imply Investors Are Overpaying?Key Insights Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is US$1.47 ADC...Buy Or Sell Opportunity • Mar 09Now 25% overvaluedOver the last 90 days, the stock has fallen 43% to US$1.84. The fair value is estimated to be US$1.47, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has grown by 4.6%. For the next 3 years, revenue is forecast to grow by 32% per annum. Earnings are also forecast to grow by 30% per annum over the same time period.분석 기사 • Feb 12Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%Unfortunately for some shareholders, the ADC Therapeutics SA ( NYSE:ADCT ) share price has dived 26% in the last thirty...Buy Or Sell Opportunity • Feb 04Now 24% overvaluedOver the last 90 days, the stock has fallen 48% to US$1.65. The fair value is estimated to be US$1.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has grown by 4.6%. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 25% per annum over the same time period.공시 • Dec 31ADC Therapeutics SA Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell LymphomaADC Therapeutics SA announced the completion of enrollment in LOTIS-5, the Phase 3 confirmatory trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with rituximab (Lonca-R) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA previously received accelerated approval for the treatment of r/r DLBCL after two or more lines of systemic therapy from the FDA in 2021. The randomized, open-label, two-part, two-arm, multicenter study is designed to confirm accelerated approval and may support potential label expansion into 2L+ in combination with rituximab. Twenty patients were enrolled in part 1 of a non-randomized safety run-in. As previously reported, the results showed an overall response rate (ORR) by central review of 80% (16/20) with a complete response (CR) rate of 50% (10/20) and no new safety signals. In part 2, patients with 2L+ DLBCL are randomized 1:1 to receive fixed-dose ZYNLONTA with rituximab or rituximab-gemcitabine-oxaliplatin (R-GemOx). The primary endpoint of LOTIS-5 is progression-free survival with secondary endpoints of overall survival, ORR, CR rate and duration of response as well as frequency and severity of adverse events. Topline results of the primary endpoint analysis are anticipated by the end of 2025 once the required number of pre-specified events is reached followed by regulatory submission to the FDA in First Quarter 2026 and potential approval in late 2026. ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.Seeking Alpha • Dec 12ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCLSummary Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL, to be released in the 1st half of 2025. The seven major Diffuse Large B-cell Lymphoma markets are expected to reach $5.25 billion by 2034. Antibody-drug conjugate with monoclonal antibody directed CD-22 ADCT-602 is being explored in a phase 1/2 study for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Read the full article on Seeking Alpha공시 • Dec 11+ 1 more updateADC Therapeutics SA Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA®? in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaADC Therapeutics SA announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Initial Clinical Data from Phase 1b LOTIS-7 Trial: LOTIS-7 is an ongoing Phase 1b global multicenter, multi-arm study in patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) including Part 1 (dose escalation) and Part 2 (dose expansion). As of the November 20, 2024 cutoff date, a total of 29 B-NHL patients from Part 1 and Part 2 across all dose levels were treated and evaluated for safety. An initial efficacy analysis was conducted on all 18 evaluable 2L+ DLBCL patients who received dose levels of 120 µg/kg (n=9) or 150 µg/kg (n=9) of ZYNLONTA plus the bispecific antibody glofitamab: Best overall response rate (ORR) was 94% (17/18) as assessed by Lugano criteria. Complete response (CR) was achieved in 72% (13/18) and partial response (PR) was achieved in 22% (4/18) of patients. Of those achieving CR, 12 out of 13 remain in CR as of the cutoff date. Among patients treated with ZYNLONTA at the 150µg/kg dose (the initial dose approved for ZYNLONTA as a monotherapy in 3L+ DLBCL patients), best ORR was 100% (9/9) and CR was achieved in 78% (7/9) of patients. Encouraging efficacy data was observed across patients with different numbers of lines and types of prior treatments and across different histologies. Initial safety data on all 29 patients suggest that ZYNLONTA plus glofitamab is generally well tolerated with no DLTs across all dose levels: Treatment emergent adverse events (TEAEs) of Grade 3 or higher occurring in = 5% of patients included neutropenia (24%), lymphopenia (7%) and hypokalemia (7%). Cytokine Release Syndrome (CRS) of Grade 1 or 2 according to ASTCT grading was observed in 34.5% of patients and resolved with standard treatment. Low-grade Immune Effector. Cell-Associated Neurotoxicity Syndrome (ICANS) (Grade 2 according to ASTCT grading) was observed in two patients and both had complete resolution of symptoms. No Grade 3 or higher CRS or ICANS were observed. There were no Grade 5 TEAEs observed.공시 • Dec 10Adc Therapeutics Sa Announces the Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating Zynlonta®? in Combination with Rituximab to Treat Relapsed/Refractory Follicular LymphomaADC Therapeutics SA announced updated data from the investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory (r/r) follicular lymphoma (FL) were published in the December issue of The Lancet Haematology, following an oral presentation of the data at the recent 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The primary endpoint of the study is complete response rate (CR) by week 12 PET/CT based on Lugano 2014 criteria. The publication titled, "Loncastuximab Tesirine with rituximab in patients with relapsed or refractory®?: a single centre, single arm Phase 2 trial," is now available online and will be published in the December issue of the Lancet Haematology.분석 기사 • Nov 16Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%ADC Therapeutics SA ( NYSE:ADCT ) shareholders won't be pleased to see that the share price has had a very rough month...Price Target Changed • Nov 10Price target decreased by 12% to US$8.60Down from US$9.80, the current price target is an average from 5 analysts. New target price is 194% above last closing price of US$2.93. Stock is up 523% over the past year. The company is forecast to post a net loss per share of US$1.60 next year compared to a net loss per share of US$2.94 last year.Reported Earnings • Nov 08Third quarter 2024 earnings: EPS misses analyst expectationsThird quarter 2024 results: US$0.42 loss per share (improved from US$0.58 loss in 3Q 2023). Revenue: US$18.5m (up 27% from 3Q 2023). Net loss: US$44.0m (loss narrowed 8.0% from 3Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.5%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 07Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2024 results: US$0.38 loss per share (improved from US$0.58 loss in 2Q 2023). Revenue: US$17.4m (down 9.7% from 2Q 2023). Net loss: US$36.5m (loss narrowed 22% from 2Q 2023). Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) exceeded analyst estimates by 17%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.공시 • Aug 07ADC Therapeutics SA has filed a Follow-on Equity Offering in the amount of $100 million.ADC Therapeutics SA has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering분석 기사 • Jul 18ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For ExcitementThose holding ADC Therapeutics SA ( NYSE:ADCT ) shares would be relieved that the share price has rebounded 34% in the...Seeking Alpha • Jun 06Limiting Concerns On ADC Therapeutics' ProspectsSummary ADC Therapeutics is developing antibody-drug conjugates for hematologic cancers and solid tumors. Their drug Zynlonta shows promise in targeting and killing cancer cells while reducing damage to healthy tissues. ADCT's pipeline includes ADCT-601 and ADCT-602 for solid tumors and acute lymphoblastic leukemia. ADCT has significant cash burn and debt, leading to financial constraints and a limited cash runway. Despite a promising pipeline, ADCT's high valuation and competitive challenges justify a "hold" rating. Read the full article on Seeking Alpha분석 기사 • May 30ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching RevenuesThe ADC Therapeutics SA ( NYSE:ADCT ) share price has fared very poorly over the last month, falling by a substantial...Major Estimate Revision • May 13Consensus EPS estimates upgraded to US$1.84 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$80.9m to US$77.7m. 2024 losses expected to reduce from -US$2.15 to -US$1.84 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target broadly unchanged at US$10.00. Share price fell 3.4% to US$4.30 over the past week.Recent Insider Transactions • May 12CEO & Director recently sold US$133k worth of stockOn the 7th of May, Ameet Mallik sold around 30k shares on-market at roughly US$4.48 per share. This transaction amounted to 2.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Ameet's only on-market trade for the last 12 months.분석 기사 • May 10Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter ResultsADC Therapeutics SA ( NYSE:ADCT ) shareholders are probably feeling a little disappointed, since its shares fell 3.4...공시 • May 10ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $105 million.ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $105 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 13,411,912 Price\Range: $4.9 Discount Per Security: $0.294 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 8,163,265 Price\Range: $4.812 Discount Per Security: $0.2887공시 • May 08ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone LymphomaADC Therapeutics SA announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL). The 50-patient single-arm, open-label Phase 2 multicenter study is currently being conducted at the Sylvester Comprehensive Cancer Center at University of Miami and City of Hope, and led by Izidore Lossos, MD, Professor, Director, Lymphoma Program at the Sylvester Comprehensive Cancer Center, University of Miami. This study is evaluating the safety and efficacy of six cycles of ZYNLONTA across 18 weeks in patients with r/r MZL previously treated with =1 line of systemic therapy (ClinicalTrials.gov identifier: NCT05296070). As of the data cutoff date of March 30, 2024, 15 patients were evaluable. Of these 15 patients evaluated, 13 achieved a complete response (CR) and one patient achieved a partial response (PR). All patients who achieved responses had maintained them at the time of the data cutoff. In this study, ZYNLONTA was generally well-tolerated and safety was consistent with the known profile, with two patient discontinuations. One patient discontinued after cycle 2 and a second patient discontinued after cycle 4 due to a toxicity, which fully resolved upon discontinuation of treatment. Both of these patients remain in CR at 10 and 6 months, respectively. These initial data were presented at the Lymphoma Research Foundation’s 2024 Marginal Zone Lymphoma Scientific Workshop by the trial’s lead investigator, Izidore Lossos, MD, Professor, Director, Lymphoma Program at the Sylvester Comprehensive Cancer Center, University of Miami. MZL is a rare, indolent non-Hodgkin lymphoma (NHL) and the third most common NHL subtype. There are few FDA-approved therapies for MZL.Reported Earnings • May 07First quarter 2024 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2024 results: US$0.56 loss per share (improved from US$0.73 loss in 1Q 2023). Revenue: US$18.1m (down 4.9% from 1Q 2023). Net loss: US$46.6m (loss narrowed 22% from 1Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.공시 • May 06ADC Therapeutics SA has filed a Follow-on Equity Offering.ADC Therapeutics SA has filed a Follow-on Equity Offering. Security Name: Common Shares Security Type: Common Stock Security Name: Pre-Funded Warrants Security Type: Equity Warrant공시 • Apr 28ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024, at 04:00 Eastern Daylight. Location: Company’s headquarters located at Biopôle, Route de la Corniche 3B, 1066 Epalinges Epalinges Switzerland Agenda: To consider approving the company’s management report, annual financial statements and consolidated financial statements for the year ended december 31, 2023 (collectively, the “reports”) and acknowledging the auditors’ reports for the year ended december 31, 2023 (the “auditors’ report”); to consider approving, on an advisory basis under swiss law, the company’s compensation report for the year ended december 31, 2023; and to transact such other business matters.Major Estimate Revision • Mar 20Consensus EPS estimates fall by 13%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$80.7m to US$82.1m. Forecast EPS reduced from -US$1.85 to -US$2.10 per share. Biotechs industry in the US expected to see average net income decline 8.2% next year. Consensus price target up from US$9.25 to US$10.00. Share price rose 4.9% to US$4.67 over the past week.Seeking Alpha • Mar 19ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)Summary ADC Therapeutics has experienced a 200%+ recovery since being undervalued and trading below their cash on hand. The company's prospects are now uncertain as they face challenges in getting a foothold for their approved antibody-drug conjugate. The success of the phase 3 trial for loncastuximab will determine the company's near-term aspirations and market sentiment. Read the full article on Seeking Alpha분석 기사 • Mar 17ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching RevenuesADC Therapeutics SA ( NYSE:ADCT ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...New Risk • Mar 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$148m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$119m net loss in 3 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).Reported Earnings • Mar 13Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: US$2.94 loss per share (further deteriorated from US$1.99 loss in FY 2022). Revenue: US$69.6m (down 67% from FY 2022). Net loss: US$240.1m (loss widened 54% from FY 2022). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) missed analyst estimates by 23%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.분석 기사 • Jan 18ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For GrowthDespite an already strong run, ADC Therapeutics SA ( NYSE:ADCT ) shares have been powering on, with a gain of 38% in...공시 • Jan 04ADC Therapeutics Regains Compliance with NYSE Continued Listing StandardsADC Therapeutics SA announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the Company has regained compliance with the continued listing minimum price criteria set in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE’s noncompliant issuers list. The Company previously received a notice from the NYSE that it was not in compliance with the continued listing minimum price criteria, as the average closing price of its common shares was below $1.00 over a consecutive 30 trading-day period. As closing price of the common shares on December 29, 2023 and the average closing price of the common shares over the 30 trading-day period ending on December 29, 2023 were both above $1.00, the deficiency was cured.Seeking Alpha • Dec 29ADC Therapeutics: Rising From The Ashes Of A Halted Drug TrialSummary ADCs are a promising development in cancer treatment, targeting specific tumors with minimal side effects. ADCT's first drug, Zynlonta, was approved for third line treatment of lymphoma, but a halted trial for second line treatment was a setback. New data shows that the combination of Zynlonta and Rituximab can cure certain types of lymphoma, and ADCT has a robust pipeline of potential therapies. Read the full article on Seeking Alpha분석 기사 • Dec 14An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is US$2.71 Current share...Seeking Alpha • Dec 01ADC Therapeutics: Navigating A Swirling DrainSummary ADC Therapeutics (ADCT) is trading well below its cash on hand, underlying its severely poor sentiment from investors. ADCT's main molecule, loncastuximab tesirine, has shown positive results in the relapse/refractory setting. ADCT has other pipeline projects in development, with data from phase 1 studies expected in the first half of 2024. Read the full article on Seeking AlphaNew Risk • Nov 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$54m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$138m net loss in 3 years). Market cap is less than US$100m (US$48.5m market cap).Reported Earnings • Nov 09Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: US$0.58 loss per share (improved from US$0.65 loss in 3Q 2022). Revenue: US$14.5m (down 81% from 3Q 2022). Net loss: US$47.8m (loss narrowed 5.5% from 3Q 2022). Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.New Risk • Nov 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$8.6m). Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$141m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$69.7m market cap).Price Target Changed • Nov 02Price target increased by 19% to US$10.50Up from US$8.80, the current price target is an average from 4 analysts. New target price is 1,400% above last closing price of US$0.70. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$2.44 next year compared to a net loss per share of US$1.99 last year.Price Target Changed • Oct 08Price target increased by 12% to US$8.80Up from US$7.83, the current price target is an average from 5 analysts. New target price is 948% above last closing price of US$0.84. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$2.47 next year compared to a net loss per share of US$1.99 last year.New Risk • Oct 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-US$8.6m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$150m net loss in 3 years). Market cap is less than US$100m (US$66.6m market cap).Major Estimate Revision • Sep 19Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$82.3m to US$73.0m. Forecast losses increased from -US$2.35 to -US$2.45 per share. Biotechs industry in the US expected to see average net income decline 3.3% next year. Consensus price target down from US$8.17 to US$7.83. Share price fell 16% to US$0.80 over the past week.공시 • Aug 31ADC Therapeutics SA Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs At the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)ADC Therapeutics SA announced that two ZYNLONTA® (loncastuximab tesirine-lpyl) abstracts have been accepted for presentation at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023), which will be held in Houston, Texas from September 6-9, 2023. LOTIS-5 Safety Run-In Results: LOTIS-5 is a Phase 3, randomized, open-label, two-part, two-arm, multicenter study of loncastuximab tesirine in combination with rituximab (Lonca-R) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is the confirmatory trial for accelerated approval for 3L+ and would also support potential label expansion into 2L+ in combination with rituximab. Twenty patients were enrolled in part 1 of a non-randomized safety run-in. In part 2, approximately 330 patients will be randomized 1:1 to receive fixed-dose Lonca-R or rituximab-gemcitabine-oxaliplatin (R-GemOx). The 20 patients in the safety run-in were a median age of 74.5 years and had previously received a median of five cycles of Lonca-R and one previous therapy. As of the April 10, 2023, data cutoff: Seven patients completed treatment and five continue in follow-up. The overall response rate by central review was 16/20 (80%). A total of 10/20 (50%) and 6/20 (30%) patients attained complete and partial response, respectively. The median duration of response was 8.0 months and the median progression-free survival was 8.3 months. A total of 11 (55%) patients had grade =3 treatment-emergent adverse events (TEAEs). The most common grade =3 TEAEs were increased gamma-glutamyltransferase (5 patients [25%]) and neutropenia (3 patients [15%]). LOTIS-7 is a multicenter and multi-arm study that will enroll approximately 200 patients with relapsed or refractory B-cell non-Hodgkin lymphoma in part 1 (dose escalation in approximately 60 patients) and part 2 (dose expansion in approximately 120 patients). Dosing arms include ZYNLONTA (loncastuximab tesirine-lpyl) plus polatuzumab vedotin, as well as ZYNLONTA (loncastuximab tesirine-lpyl) plus glofitamab and mosunetuzumab, t-cell-engaging bispecific monoclonal antibodies (BsAbs). The bispecific combination arms of the LOTIS-7 trial are now actively enrolling patients with DLBCL, including transformed follicular lymphoma (FL), high-grade B-cell lymphoma (HGBCL), follicular lymphoma (FL) and marginal zone lymphoma (MZL). Combining these agents with different mechanisms of action has the potential to have increased activity compared to either agent alone.Seeking Alpha • Aug 29ADC Therapeutics: Slowly Moving Toward SolvencySummary ADC Therapeutics is a small-cap biotech with an approved antibody-drug conjugate in lymphoma. The company has faced setbacks but has cash on hand and promising clinical data outside of their flagship product. They are trading below their enterprise value, making them a potentially strong opportunity for risk-tolerant investors. Read the full article on Seeking AlphaNew Risk • Aug 11New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$8.6m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$8.6m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$136m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (5.2% increase in shares outstanding).Major Estimate Revision • Aug 09Consensus revenue estimates decrease by 20%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$104.2m to US$83.0m. EPS estimate increased from -US$2.73 to -US$2.42 per share. Biotechs industry in the US expected to see average net income decline 20% next year. Consensus price target up from US$8.33 to US$9.40. Share price was steady at US$1.50 over the past week.New Risk • Aug 09New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$8.6m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$8.6m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$159m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (5.2% increase in shares outstanding).매출 및 비용 세부 내역ADC Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NYSE:ADCT 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 2679-13782031 Dec 2581-14380030 Sep 2575-16780030 Jun 2577-17081031 Mar 2576-15083031 Dec 2471-15886030 Sep 2471-21290030 Jun 2467-21593031 Mar 2469-22798031 Dec 2370-240106030 Sep 23123-181114030 Jun 23184-184128031 Mar 23182-200137031 Dec 22210-157143030 Sep 22157-166146030 Jun 2294-187143031 Mar 2280-195142031 Dec 2134-230136030 Sep 2117-252129030 Jun 214-200116031 Mar 210-254100031 Dec 200-24677030 Sep 200-22653030 Jun 200-23735031 Mar 201-13519031 Dec 192-11614030 Sep 193-11211030 Jun 193-11111031 Mar 192-11710031 Dec 181-1239031 Dec 172-9080양질의 수익: ADCT 은(는) 현재 수익성이 없습니다.이익 마진 증가: ADCT는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ADCT는 수익성이 없지만 지난 5년 동안 연평균 7.4%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ADCT의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ADCT은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(54.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ADCT의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/16 15:23종가2026/06/16 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ADC Therapeutics SA는 21명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Tazeen AhmadBofA Global ResearchEric SchmidtCantor Fitzgerald & Co.Naureen QuibriaCapital One Securities, Inc.18명의 분석가 더 보기
Reported Earnings • May 05First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$0.21 loss per share (improved from US$0.36 loss in 1Q 2025). Revenue: US$20.9m (down 9.5% from 1Q 2025). Net loss: US$33.0m (loss narrowed 15% from 1Q 2025). Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) missed analyst estimates by 4.1%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 10Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: US$1.12 loss per share (improved from US$1.63 loss in FY 2024). Revenue: US$81.4m (up 15% from FY 2024). Net loss: US$142.6m (loss narrowed 9.6% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 20%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 25% per year.
Reported Earnings • Nov 11Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: US$0.30 loss per share (improved from US$0.42 loss in 3Q 2024). Revenue: US$16.4m (down 11% from 3Q 2024). Net loss: US$41.0m (loss narrowed 6.8% from 3Q 2024). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) exceeded analyst estimates by 17%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 13Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2025 results: US$0.50 loss per share (further deteriorated from US$0.38 loss in 2Q 2024). Revenue: US$18.8m (up 8.2% from 2Q 2024). Net loss: US$56.6m (loss widened 55% from 2Q 2024). Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) missed analyst estimates by 4.5%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
Reported Earnings • May 15First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: US$0.36 loss per share (improved from US$0.56 loss in 1Q 2024). Revenue: US$23.0m (up 28% from 1Q 2024). Net loss: US$38.6m (loss narrowed 17% from 1Q 2024). Revenue exceeded analyst estimates by 30%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 27Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: US$1.63 loss per share (improved from US$2.94 loss in FY 2023). Revenue: US$70.8m (up 1.8% from FY 2023). Net loss: US$157.8m (loss narrowed 34% from FY 2023). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) exceeded analyst estimates by 4.1%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
내러티브 업데이트 • Jun 11ADCT: Future Earnings Potential Will Rely On Managing LOTIS-5 Safety RisksNarrative Update: ADC Therapeutics Analyst Price Target Reset Analysts have cut their average price target for ADC Therapeutics to $2, from prior estimates closer to $6. This reflects concerns about Zynlonta's risk benefit profile and added regulatory risk following the LOTIS-5 trial results.
속보 • Jun 07ZYNLONTA Study Meets Main Goal as Safety and Regulatory Questions Weigh on ADC TherapeuticsADC Therapeutics reported that its Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab in relapsed or refractory DLBCL met the primary endpoint with a statistically significant improvement in progression-free survival versus the control regimen. The trial also showed higher complete response rates and longer durations of response for the ZYNLONTA arm, while overall survival was not negatively affected compared with the control group. Regulators and investors are watching safety closely after the study revealed a higher incidence of serious adverse events, treatment-related deaths and more treatment discontinuations in the ZYNLONTA arm. RBC Capital downgraded the stock to Sector Perform following these findings. The key question now is how regulators weigh the efficacy outcomes against the reported safety issues, particularly for older patients who appeared more affected in the trial. Until there is clearer feedback from the FDA and more visibility on the timing and content of any filing, this appears to be a stock where regulatory decisions could have a significant impact on sentiment and perceived risk.
Seeking Alpha • Jun 06ADC Therapeutics: 'Sell' LOTIS-5 Underwhelms And Possible Change In StrategySummary ADC Therapeutics is downgraded from 'Strong Buy' to 'Sell' due to safety concerns in ZYNLONTA's phase 3 LOTIS-5 trial. While ZYNLONTA + rituximab met the primary PFS endpoint, the regimen showed higher serious adverse events and Grade 5 TEAEs versus the comparator. Lack of overall survival benefit and increased withdrawals further undermine the risk-benefit profile for 2nd-line r/r DLBCL expansion. Strategic alternatives, including cost reductions, are under consideration, as regulatory and commercial prospects for ZYNLONTA become uncertain. Read the full article on Seeking Alpha
Breakeven Date Change • Jun 05No longer forecast to breakevenThe 6 analysts covering ADC Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$11.8m in 2028. New consensus forecast suggests the company will make a loss of US$18.4m in 2028.
New Risk • Jun 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Negative equity (-US$216m). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding).
Price Target Changed • Jun 04Price target decreased by 15% to US$6.80Down from US$8.00, the current price target is an average from 5 analysts. New target price is 415% above last closing price of US$1.32. Stock is down 62% over the past year. The company is forecast to post a net loss per share of US$0.84 next year compared to a net loss per share of US$1.12 last year.
공시 • Jun 04ADC Therapeutics Announces Topline Results From LOTIS-5 Phase 3 Confirmatory Trial Of ZYNLONTA In Combination with Rituximab In Relapsed or Refractory Diffuse Large B-Cell LymphomaADC Therapeutics announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA plus rituximab achieved statistical significance on the trial's primary endpoint of progression-free survival (PFS) and demonstrated no detrimental effect on the key secondary efficacy endpoint of overall survival (OS). In addition, a higher complete response (CR) rate and duration of CRs (DoCR) were observed with ZYNLONTA plus rituximab. Overall, treatment emergent adverse event (TEAE) rates were similar between arms. Similar rates of overall Grade =3 TEAEs greater than 5% were observed across both arms, with hematologic TEAEs higher in the control arm and infection, hepatotoxicity, and edema/effusion higher in the test arm. Serious adverse events (SAEs), TEAEs leading to study drug withdrawal, and Grade 5 events were higher in the test arm, with the majority of Grade 5 TEAEs in the test arm occurring in patients aged 75 years or older. The LOTIS-5 trial is a randomized, open-label, two-arm, multicenter study evaluating ZYNLONTA plus rituximab versus the standard immunochemotherapy rituximab gemcitabine-oxaliplatin (R-GemOx), for the treatment of r/r DLBCL after one or more lines of systemic therapy. The study met the primary endpoint of PFS (per independent review committee) with statistical significance (HR = 0.73; p-value = 0.008 two sided), with a median PFS of 6.1 months for ZYNLONTA plus rituximab vs 4.7 months for R-GemOx. Overall survival showed no detrimental effect with ZYNLONTA plus rituximab compared to the control arm (HR = 0.96, impacted by the earlier use and a higher rate of new anti-lymphoma treatment switching in the control arm). Overall response rate (ORR) was 58.1% vs. 45.2%, CR rate was 39.5% vs. 26.7%, median duration of response (DOR) was 9.2 months vs. 7.7 months, and median DoCR was 16.8 months vs. 12.3 months for ZYNLONTA plus rituximab compared to R-GemOx, respectively. Of patients achieving CR, 48.5% vs. 16.7% remained in CR at 24 months in favor of ZYNLONTA plus rituximab. Of note, results in North America were consistent with the overall study results. Overall, TEAE rates were similar between arms (98.5% vs. 97.5%). Higher rates of SAEs were seen in the test arm (49.0% vs. 34.5%). Grade =3 TEAEs observed in > 5% of patients were hematologic (40.7% vs. 59.4%), followed by infection/infestations (24.5% vs. 15.7%), then hepatotoxicity (17.2% vs. 8.1%) and oedema/effusion (7.4% vs. 0.5%) when comparing ZYNLONTA plus rituximab to R-GemOx. A higher rate of Grade 5 TEAEs was observed in the ZYNLONTA plus rituximab arm (27 pts/13.2%) vs. R-GemOx (9 pts/4.6%). Of note, the majority of Grade 5 TEAEs in the test arm occurred in patients aged 75 years or older. Higher rates of TEAEs leading to any drug withdrawal occurred in the ZYNLONTA plus rituximab arm (25.5% vs. 9.1%). In this study, the TEAE reporting window was defined as 105 days after the last dose of study treatment or the start of new anticancer therapy, whichever is earlier. The rates of TEAEs in this study were impacted by the longer overall TEAE observation time in the test vs. control arm. This difference is primarily driven by a higher rate of and earlier switching to subsequent therapies in the control arm. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.
내러티브 업데이트 • May 28ADCT: Higher Revenue And Margin Assumptions Will Support Future Earnings PotentialAnalysts have raised their price target for ADC Therapeutics by $1, citing updated assumptions around revenue growth, profit margins, and future P/E expectations as key drivers of the revision. Analyst Commentary While the latest price target revision for ADC Therapeutics reflects updated assumptions on revenue, margins, and P/E, bearish analysts continue to flag several risks that could limit upside if execution falls short.
분석 기사 • May 07Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter ReportIt's been a good week for ADC Therapeutics SA ( NYSE:ADCT ) shareholders, because the company has just released its...
Reported Earnings • May 05First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$0.21 loss per share (improved from US$0.36 loss in 1Q 2025). Revenue: US$20.9m (down 9.5% from 1Q 2025). Net loss: US$33.0m (loss narrowed 15% from 1Q 2025). Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) missed analyst estimates by 4.1%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
내러티브 업데이트 • May 03ADCT: Updated Capital Plans And Refined Assumptions Will Support Future Upside PotentialAnalysts have increased their price target on ADC Therapeutics by $1, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E that they believe better align the valuation with current fundamentals and expectations. Analyst Commentary Despite the modest $1 lift in the price target, recent commentary around ADC Therapeutics still carries a cautious tone.
내러티브 업데이트 • Apr 19ADCT: Refined Risk And Earnings Assumptions Will Support Future Upside PotentialAnalysts raised their price target on ADC Therapeutics by $1, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that collectively fine tune their outlook rather than overhaul it. Analyst Commentary Bearish analysts are treating the latest US$1 price target adjustment as a refinement rather than a signal of strong conviction, and their commentary leans cautious around execution, valuation and growth visibility.
공시 • Apr 13ADC Therapeutics SA, Annual General Meeting, Jun 01, 2026ADC Therapeutics SA, Annual General Meeting, Jun 01, 2026, at 15:00 W. Europe Standard Time.
내러티브 업데이트 • Apr 05ADCT: Refreshed Revenue And Margin Assumptions Will Strengthen Future Earnings PowerAnalysts have lifted their price target on ADC Therapeutics by $1, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the change. Analyst Commentary While the latest price target adjustment reflects refreshed modeling on discount rates, revenue assumptions, margins and future P/E, bearish analysts are still flagging several areas of concern that they see as reasons to stay cautious.
내러티브 업데이트 • Mar 21ADCT: Higher Revenue Assumptions Will Support Stronger Future Earnings PowerAnalysts have lifted their price target fair value for ADC Therapeutics from $5.00 to $6.00, citing updated assumptions for revenue growth, profit margins and future P/E that change their overall assessment of risk and return. Valuation Changes Fair Value: raised from $5.00 to $6.00 per share, indicating a higher assessed intrinsic value.
Major Estimate Revision • Mar 17Consensus estimates of losses per share improve by 28%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from US$78.5m to US$80.8m. EPS estimate increased from -US$1.11 per share to -US$0.806 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target up from US$7.80 to US$8.00. Share price fell 14% to US$4.11 over the past week.
New Risk • Mar 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$186m). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$1.6m net loss in 3 years).
Breakeven Date Change • Mar 11No longer forecast to breakevenThe 6 analysts covering ADC Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$13.2m in 2028. New consensus forecast suggests the company will make a loss of US$1.63m in 2028.
Reported Earnings • Mar 10Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: US$1.12 loss per share (improved from US$1.63 loss in FY 2024). Revenue: US$81.4m (up 15% from FY 2024). Net loss: US$142.6m (loss narrowed 9.6% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 20%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 25% per year.
내러티브 업데이트 • Mar 04ADCT: Higher Revenue Outlook And Richer P/E Multiple Will Support UpsideAnalysts have trimmed their price target on ADC Therapeutics to $7.50 from $8.20, citing updated assumptions that combine higher projected revenue growth with lower expected profit margins and a higher future P/E multiple. Valuation Changes Fair Value: reduced from $8.20 to $7.50, a modest cut to the target level used in the model.
Price Target Changed • Mar 03Price target decreased by 8.5% to US$7.50Down from US$8.20, the current price target is an average from 4 analysts. New target price is 85% above last closing price of US$4.05. Stock is up 126% over the past year. The company is forecast to post a net loss per share of US$1.41 next year compared to a net loss per share of US$1.62 last year.
분석 기사 • Feb 05ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is LackingADC Therapeutics SA's ( NYSE:ADCT ) price-to-sales (or "P/S") ratio of 6.7x might make it look like a buy right now...
Breakeven Date Change • Dec 31Forecast to breakeven in 2028The 6 analysts covering ADC Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.26m in 2028. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$238m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding).
공시 • Dec 04ADC Therapeutics SA Announces Updated Data from Lotis-7 Phase 1B Clinical Trial of Zynlonta®? in Combination with Bispecific Antibody Supporting Potential Best-In-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaADC Therapeutics SA announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA®? in combination with the bispecific antibody glofitamab (COLUMVI®?) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Enrollment in the LOTIS-7 clinical trial is ongoing, with complete enrollment of approximately 100 patients at the selected 150 ug/kg dose expected during the first half of 2026. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or ref refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphomas (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented, the timing and outcome of the full LOTIS-7 trial, potential best-in-class results, future publication, compendia and regulatory strategy and the commercial opportunity; the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the strengthened balance sheet and expected cash run into at least 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA revenue in the United States and potential peak revenue; the ability of partners to commercialize ZYNLONTA in foreign markets, the timing and amount of future revenue and payments to the company from such partnerships and their ability to obtain regulatory approval for ZYNLONTA™? in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for their excan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for the Company's indebtedness; and the company's indebtedness; and the ability to obtain financial and other assets for the Company's indebtedness.
공시 • Dec 03ADC Therapeutics SA to Provide Update on LOTIS-7 Clinical TrialADC Therapeutics SA announced to provide an update on the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker.
Reported Earnings • Nov 11Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: US$0.30 loss per share (improved from US$0.42 loss in 3Q 2024). Revenue: US$16.4m (down 11% from 3Q 2024). Net loss: US$41.0m (loss narrowed 6.8% from 3Q 2024). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) exceeded analyst estimates by 17%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공시 • Oct 14ADC Therapeutics SA announced that it expects to receive $60.02 million in funding from TCG Crossover Management, LLC, Redmile Group, LLCADC Therapeutics SA announced a private placement and entered into a purchase agreement to issue 11,300,000 common shares at a price of $4 per share for aggregate proceeds of $45,200,000 and 3,800,000 Pre-funded warrants at a price of $3.9 per warrant for aggregate proceeds of $14,820,000 and total gross proceeds amounting to $60,020,000. The pre-funded warrants will have an exercise price of $0.099. The transaction is expected to close on October 27, 2025, and will include participation from lead investor TCGX and Redmile Group among other Investors.
분석 기사 • Sep 30ADC Therapeutics SA (NYSE:ADCT) Held Back By Insufficient Growth Even After Shares Climb 31%Despite an already strong run, ADC Therapeutics SA ( NYSE:ADCT ) shares have been powering on, with a gain of 31% in...
Reported Earnings • Aug 13Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2025 results: US$0.50 loss per share (further deteriorated from US$0.38 loss in 2Q 2024). Revenue: US$18.8m (up 8.2% from 2Q 2024). Net loss: US$56.6m (loss widened 55% from 2Q 2024). Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) missed analyst estimates by 4.5%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Aug 12Consensus EPS estimates fall by 14%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$1.52 to -US$1.73 per share. Revenue forecast of US$78.9m unchanged since last update. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$8.20 unchanged from last update. Share price rose 6.5% to US$2.94 over the past week.
New Risk • Jul 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$238m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$103m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding).
공시 • Jun 30+ 5 more updatesADC Therapeutics SA(NYSE:ADCT) dropped from Russell 3000E Value IndexADC Therapeutics SA(NYSE:ADCT) dropped from Russell 3000E Value Index
공시 • Jun 18ADC Therapeutics SA Announces Updated ZYNLONTA®? Investigator-Initiated Trial Data in R/R Marginal Zone LymphomaADC Therapeutics SA announced updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA® to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented during a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on June 20. In addition to the MZL poster presentation at ICML, an oral encore presentation of the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) will also be presented at ICML June 20 at 3:00 p.m. CEST. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed and refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphom (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. Factors that may cause such differences include, but are not limited to: future safety and efficacy results of the Phase 2 IIT in MZL and any regulatory or compendia pathways; the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA revenue in the United States and potential peak revenue; the ability of partners to commercialize ZYNLONTA in foreign markets, the timing and amount of future revenue and payments to the company's such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by the Company's activities by the U.S. and the restrictions imposed on the company's activities by the company's activities by the Company's financial and financial requirements.
Price Target Changed • Jun 15Price target increased by 7.3% to US$8.80Up from US$8.20, the current price target is an average from 5 analysts. New target price is 146% above last closing price of US$3.58. Stock is up 8.5% over the past year. The company is forecast to post a net loss per share of US$1.57 next year compared to a net loss per share of US$1.62 last year.
공시 • Jun 13ADC Therapeutics SA announced that it expects to receive $100.000002 million in funding from Redmile Group, LLC and other invetsorsADC Therapeutics SA announced that it has entered into a securities purchase agreement to issue 13,031,161 common shares at a price of $3.53 per share for the gross proceeds of $45,999,998.33, 15,734,267 pre-funded warrant at a price of $3.432 per warrant for the gross proceeds of $54,000,004.344 for the total gross proceeds of $100,000,002.674 on June 11, 2025. The warrants will exercisable into 15,734,267 common shares. The pre-funded warrants are exercisable at any time after their original issuance until the tenth anniversary of their original issuance. At any time during the last 90 days of the term, the holder may exchange the pre-funded warrant for, and the Company will issue, a new pre-funded warrant for the number of common shares then remaining under the pre-funded warrant. The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part (but not for less than a common share) by delivering to the Company a duly executed exercise notice and by payment of the aggregate exercise price; provided that any exercise of the pre-funded warrants must be for at least 50,000 common shares (or, if less, the remaining common shares available for purchase under the pre-funded warrants).The transaction will include participation from lead investor, Redmile Group, LLC and includes participation from other institutional investors. The transaction is expected to close on June 16, 2025, subject to customary closing conditions.
공시 • Jun 12Adc Therapeutics Announces Updated Data from Lotis-7 Clinical Trial Presented At the European Hematology Association 2025 CongressADC Therapeutics SA announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) to be presented at the European Hematology Association 2025 Congress (EHA2025) in Milan, Italy. The Company will host a conference call and webcast featuring LOTIS-7 trial principal investigator and EHA presenting author, Juan Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine June 12, 2025 at 8:00 a.m. ET to discuss the results. The presentation highlights updated data as of April 14, 2025, in which r/r LBCL patients received dose levels of 120 µg/kg or 150 µg/kg of ZYNLONTA plus the bispecific antibody glofitamab, with 41 patients evaluable for safety and 30 patients evaluable for efficacy. Key highlights of the LOTIS-7 data presentation are as follows: Best overall response data among the 30 efficacy evaluable patients shows overall response rate (ORR) of 93.3% (28/30 pts) as assessed by Lugano Criteria; Complete response (CR) rate of 86.7% (26/30 pts); Of these, 25/26 patients achieving CR remain in CR as of the data cut-off; Median time to CR in 120 µg/kg = 80 days, Median time to CR in 150 µg/kg = 42 days; 12 patients converted from stable disease (SD) or partial response (PR) to CR over time (1 and 11 pts respectively); Of the 6 patients previously treated with CAR-T and undergoing response assessment, 5 achieved a CR; Among the 41 safety evaluable patients, the combination was generally well tolerated with a manageable safety profile and no DLTs across dose levels; Grade 3 or higher treatment emergent adverse events (TEAEs) observed in > 5% of patients included neutropenia (24.4%), anemia (9.8%), AST increased (7.3%), GGT increased (7.3%), and thrombocytopenia (7.3%); In the 150 µg/kg dose, cytokine release syndrome (CRS) (23.8%), all of which were Grade 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) (4.8%), with one case of Grade 2, were observed; In the 120 µg/kg dose, CRS all grades (55%), all of which were Grade 1/2 except one case of Grade 3, and ICANS (10%), with one case of Grade 1 and one case of Grade 2, were observed; TEAEs leading to discontinuation included 3 each for ZYNLONTA and glofitamab; There were no Grade 5 TEAEs observed. This data will be shared at EHA2025 during a poster presentation on June 14 at 6:30 p.m. CEST and also as an oral encore presentation at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20 at 9:00 a.m. ET. The Company plans to share additional data before the end of 2025.
공시 • Jun 06ADC Therapeutics SA Elects Timothy Coughlin as DirectorADC Therapeutics SA announced that at its AGM held on June 3, 2025, elected Timothy Coughlin as director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2026 annual general meeting of shareholders. Timothy Coughlin, 58, became a member of board of directors upon election at the Annual Meeting. From 2002 to 2018, Mr. Coughlin was with Neurocrine Biosciences, becoming the Chief Financial Officer of Neurocrine Biosciences in 2006. Prior to joining Neurocrine, he was with Catholic Health Initiatives, where he served as Vice President of Financial Services. He also served on the board of directors of Peloton Therapeutics prior to its sale to Merck & Co in 2019 and Fate Therapeutics from 2013 to 2025. In addition to board of directors, he currently serves on the board of directors of Travere Therapeutics and is chairman of the board at aTyr Pharma. Mr. Coughlin holds a master’s degree in international business from San Diego State University and a bachelor’s degree in accounting from Temple University. Mr. Coughlin is a certified public accountant (CPA) in both California and Pennsylvania.
분석 기사 • May 27Shareholders Will Likely Find ADC Therapeutics SA's (NYSE:ADCT) CEO Compensation AcceptableKey Insights ADC Therapeutics to hold its Annual General Meeting on 3rd of June CEO Ameet Mallik's total compensation...
분석 기사 • May 17Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest ResultsADC Therapeutics SA ( NYSE:ADCT ) just released its first-quarter report and things are looking bullish. Results...
Reported Earnings • May 15First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: US$0.36 loss per share (improved from US$0.56 loss in 1Q 2024). Revenue: US$23.0m (up 28% from 1Q 2024). Net loss: US$38.6m (loss narrowed 17% from 1Q 2024). Revenue exceeded analyst estimates by 30%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
공시 • May 15ADC Therapeutics SA Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)ADC Therapeutics SA announced data presentations from the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with glofitamab in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Updated results will be shared at the European Hematology Association 2025 Congress (EHA2025) taking place in Milan, Italy with an oral core presentation at the 18thInternational Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. Updated LOTIS-5 safety run-in data evaluating the combination of ZYNLONTA plus rituximab (Lonca-R) will also be featured at EHA2025. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (lofitamab tesirine- LPyl) for the treatment of adult patients with relapsed or refractory (r/r") large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphomas (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ADC Therapeutics' CD19-directed ADC ZYNLONTA (lancastuximab tesIRine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymph cancer after two or more lines ofsystem therapy, including diffuse large B -cell lymphoma (DLBC Lonca-R) not otherwise specified (N OS), DLBCL arising from high-grade lymphoma and also low-grade B-cell lymphomas. This indication is approved by The FDA under accelerated approval and in The European Union under conditional approval based On overall response rate and continued approval of this indication may be contingent upon verify and description of clinical benefit in an confirmatory trial. ADC Theraputics' CD19-directed AD19-directed ADC ZY NLONTA (loncastuxIMab tesirine-LPyl) received accelerated approval by The FDA and conditional approval from the Europe Commission for the treatment of rel relapsed or refractory large B-cell lymphoma After two or more lines of systemic treatment. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA revenue in the United States; the ability of partners to commercialize ZYNLONTA in foreign markets, the timing and amount of future revenue and payments to the company from such partnerships and their ability to obtain regulatory approval for ZYNLONTA®? in foreign markets, the timing & amount of future revenue and payments of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, ADCT 602, as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Health Health and Drug Administration (ADCs) and the Company's indebtedness, and the Company's debt and Drug Administration (ADCs).
공시 • Apr 22ADC Therapeutics SA, Annual General Meeting, Jun 03, 2025ADC Therapeutics SA, Annual General Meeting, Jun 03, 2025. Location: at the company headquarters, at biopole, route de la corniche 3b, switzerland., epalinges United States
분석 기사 • Apr 04ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching RevenuesUnfortunately for some shareholders, the ADC Therapeutics SA ( NYSE:ADCT ) share price has dived 31% in the last thirty...
새로운 내러티브 • Apr 03Expanding ZYNLONTA Trials Will Broaden DLBCL Treatment Options Expanding ZYNLONTA into earlier lines of DLBCL through trials could significantly boost revenue by accessing a larger patient population.
Reported Earnings • Mar 27Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: US$1.63 loss per share (improved from US$2.94 loss in FY 2023). Revenue: US$70.8m (up 1.8% from FY 2023). Net loss: US$157.8m (loss narrowed 34% from FY 2023). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) exceeded analyst estimates by 4.1%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
Seeking Alpha • Mar 25ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025Summary ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million in cash but faces a net loss, with a cash runway of approximately two years. The company's near-term success hinges on the results of the LOTIS-5 trial, crucial for confirming Zynlonta's efficacy and potential market expansion. Despite a challenging competitive landscape, ADCT's current valuation and cash position make it a high-risk/high-reward investment, meriting a "Buy" sentiment with caution. Read the full article on Seeking Alpha
분석 기사 • Mar 10Does This Valuation Of ADC Therapeutics SA (NYSE:ADCT) Imply Investors Are Overpaying?Key Insights Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is US$1.47 ADC...
Buy Or Sell Opportunity • Mar 09Now 25% overvaluedOver the last 90 days, the stock has fallen 43% to US$1.84. The fair value is estimated to be US$1.47, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has grown by 4.6%. For the next 3 years, revenue is forecast to grow by 32% per annum. Earnings are also forecast to grow by 30% per annum over the same time period.
분석 기사 • Feb 12Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%Unfortunately for some shareholders, the ADC Therapeutics SA ( NYSE:ADCT ) share price has dived 26% in the last thirty...
Buy Or Sell Opportunity • Feb 04Now 24% overvaluedOver the last 90 days, the stock has fallen 48% to US$1.65. The fair value is estimated to be US$1.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Earnings per share has grown by 4.6%. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 25% per annum over the same time period.
공시 • Dec 31ADC Therapeutics SA Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell LymphomaADC Therapeutics SA announced the completion of enrollment in LOTIS-5, the Phase 3 confirmatory trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with rituximab (Lonca-R) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA previously received accelerated approval for the treatment of r/r DLBCL after two or more lines of systemic therapy from the FDA in 2021. The randomized, open-label, two-part, two-arm, multicenter study is designed to confirm accelerated approval and may support potential label expansion into 2L+ in combination with rituximab. Twenty patients were enrolled in part 1 of a non-randomized safety run-in. As previously reported, the results showed an overall response rate (ORR) by central review of 80% (16/20) with a complete response (CR) rate of 50% (10/20) and no new safety signals. In part 2, patients with 2L+ DLBCL are randomized 1:1 to receive fixed-dose ZYNLONTA with rituximab or rituximab-gemcitabine-oxaliplatin (R-GemOx). The primary endpoint of LOTIS-5 is progression-free survival with secondary endpoints of overall survival, ORR, CR rate and duration of response as well as frequency and severity of adverse events. Topline results of the primary endpoint analysis are anticipated by the end of 2025 once the required number of pre-specified events is reached followed by regulatory submission to the FDA in First Quarter 2026 and potential approval in late 2026. ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Seeking Alpha • Dec 12ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCLSummary Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL, to be released in the 1st half of 2025. The seven major Diffuse Large B-cell Lymphoma markets are expected to reach $5.25 billion by 2034. Antibody-drug conjugate with monoclonal antibody directed CD-22 ADCT-602 is being explored in a phase 1/2 study for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Read the full article on Seeking Alpha
공시 • Dec 11+ 1 more updateADC Therapeutics SA Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA®? in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaADC Therapeutics SA announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Initial Clinical Data from Phase 1b LOTIS-7 Trial: LOTIS-7 is an ongoing Phase 1b global multicenter, multi-arm study in patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) including Part 1 (dose escalation) and Part 2 (dose expansion). As of the November 20, 2024 cutoff date, a total of 29 B-NHL patients from Part 1 and Part 2 across all dose levels were treated and evaluated for safety. An initial efficacy analysis was conducted on all 18 evaluable 2L+ DLBCL patients who received dose levels of 120 µg/kg (n=9) or 150 µg/kg (n=9) of ZYNLONTA plus the bispecific antibody glofitamab: Best overall response rate (ORR) was 94% (17/18) as assessed by Lugano criteria. Complete response (CR) was achieved in 72% (13/18) and partial response (PR) was achieved in 22% (4/18) of patients. Of those achieving CR, 12 out of 13 remain in CR as of the cutoff date. Among patients treated with ZYNLONTA at the 150µg/kg dose (the initial dose approved for ZYNLONTA as a monotherapy in 3L+ DLBCL patients), best ORR was 100% (9/9) and CR was achieved in 78% (7/9) of patients. Encouraging efficacy data was observed across patients with different numbers of lines and types of prior treatments and across different histologies. Initial safety data on all 29 patients suggest that ZYNLONTA plus glofitamab is generally well tolerated with no DLTs across all dose levels: Treatment emergent adverse events (TEAEs) of Grade 3 or higher occurring in = 5% of patients included neutropenia (24%), lymphopenia (7%) and hypokalemia (7%). Cytokine Release Syndrome (CRS) of Grade 1 or 2 according to ASTCT grading was observed in 34.5% of patients and resolved with standard treatment. Low-grade Immune Effector. Cell-Associated Neurotoxicity Syndrome (ICANS) (Grade 2 according to ASTCT grading) was observed in two patients and both had complete resolution of symptoms. No Grade 3 or higher CRS or ICANS were observed. There were no Grade 5 TEAEs observed.
공시 • Dec 10Adc Therapeutics Sa Announces the Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating Zynlonta®? in Combination with Rituximab to Treat Relapsed/Refractory Follicular LymphomaADC Therapeutics SA announced updated data from the investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory (r/r) follicular lymphoma (FL) were published in the December issue of The Lancet Haematology, following an oral presentation of the data at the recent 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The primary endpoint of the study is complete response rate (CR) by week 12 PET/CT based on Lugano 2014 criteria. The publication titled, "Loncastuximab Tesirine with rituximab in patients with relapsed or refractory®?: a single centre, single arm Phase 2 trial," is now available online and will be published in the December issue of the Lancet Haematology.
분석 기사 • Nov 16Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%ADC Therapeutics SA ( NYSE:ADCT ) shareholders won't be pleased to see that the share price has had a very rough month...
Price Target Changed • Nov 10Price target decreased by 12% to US$8.60Down from US$9.80, the current price target is an average from 5 analysts. New target price is 194% above last closing price of US$2.93. Stock is up 523% over the past year. The company is forecast to post a net loss per share of US$1.60 next year compared to a net loss per share of US$2.94 last year.
Reported Earnings • Nov 08Third quarter 2024 earnings: EPS misses analyst expectationsThird quarter 2024 results: US$0.42 loss per share (improved from US$0.58 loss in 3Q 2023). Revenue: US$18.5m (up 27% from 3Q 2023). Net loss: US$44.0m (loss narrowed 8.0% from 3Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.5%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 07Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2024 results: US$0.38 loss per share (improved from US$0.58 loss in 2Q 2023). Revenue: US$17.4m (down 9.7% from 2Q 2023). Net loss: US$36.5m (loss narrowed 22% from 2Q 2023). Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) exceeded analyst estimates by 17%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
공시 • Aug 07ADC Therapeutics SA has filed a Follow-on Equity Offering in the amount of $100 million.ADC Therapeutics SA has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
분석 기사 • Jul 18ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For ExcitementThose holding ADC Therapeutics SA ( NYSE:ADCT ) shares would be relieved that the share price has rebounded 34% in the...
Seeking Alpha • Jun 06Limiting Concerns On ADC Therapeutics' ProspectsSummary ADC Therapeutics is developing antibody-drug conjugates for hematologic cancers and solid tumors. Their drug Zynlonta shows promise in targeting and killing cancer cells while reducing damage to healthy tissues. ADCT's pipeline includes ADCT-601 and ADCT-602 for solid tumors and acute lymphoblastic leukemia. ADCT has significant cash burn and debt, leading to financial constraints and a limited cash runway. Despite a promising pipeline, ADCT's high valuation and competitive challenges justify a "hold" rating. Read the full article on Seeking Alpha
분석 기사 • May 30ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching RevenuesThe ADC Therapeutics SA ( NYSE:ADCT ) share price has fared very poorly over the last month, falling by a substantial...
Major Estimate Revision • May 13Consensus EPS estimates upgraded to US$1.84 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$80.9m to US$77.7m. 2024 losses expected to reduce from -US$2.15 to -US$1.84 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target broadly unchanged at US$10.00. Share price fell 3.4% to US$4.30 over the past week.
Recent Insider Transactions • May 12CEO & Director recently sold US$133k worth of stockOn the 7th of May, Ameet Mallik sold around 30k shares on-market at roughly US$4.48 per share. This transaction amounted to 2.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Ameet's only on-market trade for the last 12 months.
분석 기사 • May 10Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter ResultsADC Therapeutics SA ( NYSE:ADCT ) shareholders are probably feeling a little disappointed, since its shares fell 3.4...
공시 • May 10ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $105 million.ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $105 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 13,411,912 Price\Range: $4.9 Discount Per Security: $0.294 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 8,163,265 Price\Range: $4.812 Discount Per Security: $0.2887
공시 • May 08ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone LymphomaADC Therapeutics SA announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL). The 50-patient single-arm, open-label Phase 2 multicenter study is currently being conducted at the Sylvester Comprehensive Cancer Center at University of Miami and City of Hope, and led by Izidore Lossos, MD, Professor, Director, Lymphoma Program at the Sylvester Comprehensive Cancer Center, University of Miami. This study is evaluating the safety and efficacy of six cycles of ZYNLONTA across 18 weeks in patients with r/r MZL previously treated with =1 line of systemic therapy (ClinicalTrials.gov identifier: NCT05296070). As of the data cutoff date of March 30, 2024, 15 patients were evaluable. Of these 15 patients evaluated, 13 achieved a complete response (CR) and one patient achieved a partial response (PR). All patients who achieved responses had maintained them at the time of the data cutoff. In this study, ZYNLONTA was generally well-tolerated and safety was consistent with the known profile, with two patient discontinuations. One patient discontinued after cycle 2 and a second patient discontinued after cycle 4 due to a toxicity, which fully resolved upon discontinuation of treatment. Both of these patients remain in CR at 10 and 6 months, respectively. These initial data were presented at the Lymphoma Research Foundation’s 2024 Marginal Zone Lymphoma Scientific Workshop by the trial’s lead investigator, Izidore Lossos, MD, Professor, Director, Lymphoma Program at the Sylvester Comprehensive Cancer Center, University of Miami. MZL is a rare, indolent non-Hodgkin lymphoma (NHL) and the third most common NHL subtype. There are few FDA-approved therapies for MZL.
Reported Earnings • May 07First quarter 2024 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2024 results: US$0.56 loss per share (improved from US$0.73 loss in 1Q 2023). Revenue: US$18.1m (down 4.9% from 1Q 2023). Net loss: US$46.6m (loss narrowed 22% from 1Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
공시 • May 06ADC Therapeutics SA has filed a Follow-on Equity Offering.ADC Therapeutics SA has filed a Follow-on Equity Offering. Security Name: Common Shares Security Type: Common Stock Security Name: Pre-Funded Warrants Security Type: Equity Warrant
공시 • Apr 28ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024, at 04:00 Eastern Daylight. Location: Company’s headquarters located at Biopôle, Route de la Corniche 3B, 1066 Epalinges Epalinges Switzerland Agenda: To consider approving the company’s management report, annual financial statements and consolidated financial statements for the year ended december 31, 2023 (collectively, the “reports”) and acknowledging the auditors’ reports for the year ended december 31, 2023 (the “auditors’ report”); to consider approving, on an advisory basis under swiss law, the company’s compensation report for the year ended december 31, 2023; and to transact such other business matters.
Major Estimate Revision • Mar 20Consensus EPS estimates fall by 13%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$80.7m to US$82.1m. Forecast EPS reduced from -US$1.85 to -US$2.10 per share. Biotechs industry in the US expected to see average net income decline 8.2% next year. Consensus price target up from US$9.25 to US$10.00. Share price rose 4.9% to US$4.67 over the past week.
Seeking Alpha • Mar 19ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)Summary ADC Therapeutics has experienced a 200%+ recovery since being undervalued and trading below their cash on hand. The company's prospects are now uncertain as they face challenges in getting a foothold for their approved antibody-drug conjugate. The success of the phase 3 trial for loncastuximab will determine the company's near-term aspirations and market sentiment. Read the full article on Seeking Alpha
분석 기사 • Mar 17ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching RevenuesADC Therapeutics SA ( NYSE:ADCT ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...
New Risk • Mar 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$148m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$119m net loss in 3 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
Reported Earnings • Mar 13Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: US$2.94 loss per share (further deteriorated from US$1.99 loss in FY 2022). Revenue: US$69.6m (down 67% from FY 2022). Net loss: US$240.1m (loss widened 54% from FY 2022). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) missed analyst estimates by 23%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
분석 기사 • Jan 18ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For GrowthDespite an already strong run, ADC Therapeutics SA ( NYSE:ADCT ) shares have been powering on, with a gain of 38% in...
공시 • Jan 04ADC Therapeutics Regains Compliance with NYSE Continued Listing StandardsADC Therapeutics SA announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the Company has regained compliance with the continued listing minimum price criteria set in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE’s noncompliant issuers list. The Company previously received a notice from the NYSE that it was not in compliance with the continued listing minimum price criteria, as the average closing price of its common shares was below $1.00 over a consecutive 30 trading-day period. As closing price of the common shares on December 29, 2023 and the average closing price of the common shares over the 30 trading-day period ending on December 29, 2023 were both above $1.00, the deficiency was cured.
Seeking Alpha • Dec 29ADC Therapeutics: Rising From The Ashes Of A Halted Drug TrialSummary ADCs are a promising development in cancer treatment, targeting specific tumors with minimal side effects. ADCT's first drug, Zynlonta, was approved for third line treatment of lymphoma, but a halted trial for second line treatment was a setback. New data shows that the combination of Zynlonta and Rituximab can cure certain types of lymphoma, and ADCT has a robust pipeline of potential therapies. Read the full article on Seeking Alpha
분석 기사 • Dec 14An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is US$2.71 Current share...
Seeking Alpha • Dec 01ADC Therapeutics: Navigating A Swirling DrainSummary ADC Therapeutics (ADCT) is trading well below its cash on hand, underlying its severely poor sentiment from investors. ADCT's main molecule, loncastuximab tesirine, has shown positive results in the relapse/refractory setting. ADCT has other pipeline projects in development, with data from phase 1 studies expected in the first half of 2024. Read the full article on Seeking Alpha
New Risk • Nov 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$54m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$138m net loss in 3 years). Market cap is less than US$100m (US$48.5m market cap).
Reported Earnings • Nov 09Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: US$0.58 loss per share (improved from US$0.65 loss in 3Q 2022). Revenue: US$14.5m (down 81% from 3Q 2022). Net loss: US$47.8m (loss narrowed 5.5% from 3Q 2022). Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
New Risk • Nov 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$8.6m). Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$141m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$69.7m market cap).
Price Target Changed • Nov 02Price target increased by 19% to US$10.50Up from US$8.80, the current price target is an average from 4 analysts. New target price is 1,400% above last closing price of US$0.70. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$2.44 next year compared to a net loss per share of US$1.99 last year.
Price Target Changed • Oct 08Price target increased by 12% to US$8.80Up from US$7.83, the current price target is an average from 5 analysts. New target price is 948% above last closing price of US$0.84. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$2.47 next year compared to a net loss per share of US$1.99 last year.
New Risk • Oct 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-US$8.6m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$150m net loss in 3 years). Market cap is less than US$100m (US$66.6m market cap).
Major Estimate Revision • Sep 19Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$82.3m to US$73.0m. Forecast losses increased from -US$2.35 to -US$2.45 per share. Biotechs industry in the US expected to see average net income decline 3.3% next year. Consensus price target down from US$8.17 to US$7.83. Share price fell 16% to US$0.80 over the past week.
공시 • Aug 31ADC Therapeutics SA Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs At the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)ADC Therapeutics SA announced that two ZYNLONTA® (loncastuximab tesirine-lpyl) abstracts have been accepted for presentation at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023), which will be held in Houston, Texas from September 6-9, 2023. LOTIS-5 Safety Run-In Results: LOTIS-5 is a Phase 3, randomized, open-label, two-part, two-arm, multicenter study of loncastuximab tesirine in combination with rituximab (Lonca-R) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is the confirmatory trial for accelerated approval for 3L+ and would also support potential label expansion into 2L+ in combination with rituximab. Twenty patients were enrolled in part 1 of a non-randomized safety run-in. In part 2, approximately 330 patients will be randomized 1:1 to receive fixed-dose Lonca-R or rituximab-gemcitabine-oxaliplatin (R-GemOx). The 20 patients in the safety run-in were a median age of 74.5 years and had previously received a median of five cycles of Lonca-R and one previous therapy. As of the April 10, 2023, data cutoff: Seven patients completed treatment and five continue in follow-up. The overall response rate by central review was 16/20 (80%). A total of 10/20 (50%) and 6/20 (30%) patients attained complete and partial response, respectively. The median duration of response was 8.0 months and the median progression-free survival was 8.3 months. A total of 11 (55%) patients had grade =3 treatment-emergent adverse events (TEAEs). The most common grade =3 TEAEs were increased gamma-glutamyltransferase (5 patients [25%]) and neutropenia (3 patients [15%]). LOTIS-7 is a multicenter and multi-arm study that will enroll approximately 200 patients with relapsed or refractory B-cell non-Hodgkin lymphoma in part 1 (dose escalation in approximately 60 patients) and part 2 (dose expansion in approximately 120 patients). Dosing arms include ZYNLONTA (loncastuximab tesirine-lpyl) plus polatuzumab vedotin, as well as ZYNLONTA (loncastuximab tesirine-lpyl) plus glofitamab and mosunetuzumab, t-cell-engaging bispecific monoclonal antibodies (BsAbs). The bispecific combination arms of the LOTIS-7 trial are now actively enrolling patients with DLBCL, including transformed follicular lymphoma (FL), high-grade B-cell lymphoma (HGBCL), follicular lymphoma (FL) and marginal zone lymphoma (MZL). Combining these agents with different mechanisms of action has the potential to have increased activity compared to either agent alone.
Seeking Alpha • Aug 29ADC Therapeutics: Slowly Moving Toward SolvencySummary ADC Therapeutics is a small-cap biotech with an approved antibody-drug conjugate in lymphoma. The company has faced setbacks but has cash on hand and promising clinical data outside of their flagship product. They are trading below their enterprise value, making them a potentially strong opportunity for risk-tolerant investors. Read the full article on Seeking Alpha
New Risk • Aug 11New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$8.6m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$8.6m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$136m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (5.2% increase in shares outstanding).
Major Estimate Revision • Aug 09Consensus revenue estimates decrease by 20%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$104.2m to US$83.0m. EPS estimate increased from -US$2.73 to -US$2.42 per share. Biotechs industry in the US expected to see average net income decline 20% next year. Consensus price target up from US$8.33 to US$9.40. Share price was steady at US$1.50 over the past week.
New Risk • Aug 09New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$8.6m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$8.6m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$159m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (5.2% increase in shares outstanding).
